Abstract
The precision medicine (PM) revolution is well underway, and next-generation sequencing (NGS) is helping take cancer treatment to new levels. Finding actionable targets in real time is now a reality, and data from several clinical trials based on identified molecular alterations can be assessed and can help address the question of whether personalized treatment based on genomics produces superior survival outcomes compared with unselected treatment. Targeted treatment-based clinical trials have shown benefit in molecular subgroups of patients. Of further interest, it appears that genomics and immunotherapy are coupled to each other, since the immune system recognizes neo-antigens produced by the mutanome. Hence, some of the most important markers predicting response to immunotherapy are genomic markers, PDL1 amplification (for PD-1/PD-L1 checkpoint inhibitors), and tumor mutational burden. However, a number of challenges remain to be addressed if the use of molecular profiling-guided therapy in PM-designed clinical trials is to become the standard on which cancer treatment is based. In this chapter, we explore what it will take for PM trials that use molecular profiling as part of the eligibility criteria to be successful and the remaining hurdles that need to be overcome.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Catenacci DV. Next-generation clinical trials: novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol. 2015;9(5):967–96.
Schwaederle M, Zhao M, Lee JJ, et al. Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis. JAMA Oncol. 2016; https://doi.org/10.1001/jamaoncol.2016.2129.
Schwaederle M, Zhao M, Lee JJ, et al. Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. J Clin Oncol. 2015;33(32):3817–25.
Jardim DL, Schwaederle M, Wei C, et al. Impact of a biomarker-based strategy on oncology drug development: a meta-analysis of clinical trials leading to FDA approval. J Natl Cancer Inst. 2015;107(11).
West HJ. No solid evidence, only hollow argument for universal tumor sequencing: show me the data. JAMA Oncol. 2016;2(6):717–8.
Subbiah V, Kurzrock R. Universal genomic testing needed to win the war against cancer: genomics IS the diagnosis. JAMA Oncol. 2016;2(6):719–20.
Prasad V. Perspective: the precision-oncology illusion. Nature. 2016;537(7619):S63.
Le Tourneau C, Delord JP, Goncalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015;16(13):1324–34.
Le Tourneau C, Kurzrock R. Targeted therapies: what have we learned from SHIVA? Nat Rev Clin Oncol. 2016; https://doi.org/10.1038/nrclinonc.2016.164.
Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011;1(1):44–53.
Von Hoff DD, Stephenson JJ Jr, Rosen P, et al. Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol. 2010;28(33):4877–83.
Massard C, Michiels S, Ferte C, et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 2017; https://doi.org/10.1158/2159-8290.CD-16-1396.
Rodon J, Soria JC, Berger R, et al. Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a worldwide innovative network (WIN) consortium trial. Ann Oncol. 2015;26(8):1791–8.
Wheler JJ, Janku F, Naing A, et al. Cancer therapy directed by comprehensive genomic profiling: a single center study. Cancer Res. 2016;76(13):3690–701.
Kummar S, Mickey WP, Lih C-J, et al. Application of molecular profiling in clinical trials for advanced metastatic cancers. J Nat Cancer Inst. 2015;107(4):djv003.
Acknowledgments
We would like to acknowledge the Avera Cancer Institute, Sioux Falls, SD, for providing support for our research.
Conflicts of Interest
The authors have no conflicts of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Abramovitz, M. et al. (2019). Precision Medicine Clinical Trials: Successes and Disappointments, Challenges and Opportunities – Lessons Learnt. In: Badve, S., Kumar, G. (eds) Predictive Biomarkers in Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-95228-4_53
Download citation
DOI: https://doi.org/10.1007/978-3-319-95228-4_53
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95227-7
Online ISBN: 978-3-319-95228-4
eBook Packages: MedicineMedicine (R0)